{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Computerized+Tomography+%28CT%29%2F+Magnetic+Resonance+Imaging+%28MRI%29&page=30",
    "query": {
      "intervention": "Computerized Tomography (CT)/ Magnetic Resonance Imaging (MRI)",
      "page": 30
    },
    "page_size": 10
  },
  "pagination": {
    "page": 30,
    "page_size": 10,
    "total_count": 1044,
    "total_pages": 105,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Computerized+Tomography+%28CT%29%2F+Magnetic+Resonance+Imaging+%28MRI%29&page=31&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Computerized+Tomography+%28CT%29%2F+Magnetic+Resonance+Imaging+%28MRI%29&page=29&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-22T21:30:04.208Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03707184",
      "title": "Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Prostate Carcinoma",
        "Prostate Carcinoma Metastatic in the Bone",
        "Stage IV Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Fluciclovine F18",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 17,
      "start_date": "2018-10-02",
      "completion_date": "2022-02-03",
      "has_results": true,
      "last_update_posted_date": "2024-11-29",
      "last_synced_at": "2026-11-22T21:30:04.208Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03707184"
    },
    {
      "nct_id": "NCT06770582",
      "title": "Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Muscle Invasive Bladder Urothelial Carcinoma",
        "Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma",
        "Stage I Bladder Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Mitomycin",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2025-06-03",
      "completion_date": "2032-02-01",
      "has_results": false,
      "last_update_posted_date": "2026-11-09",
      "last_synced_at": "2026-11-22T21:30:04.208Z",
      "location_count": 145,
      "location_summary": "Tucson, Arizona • Fayetteville, Arkansas • Rogers, Arkansas + 103 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06770582"
    },
    {
      "nct_id": "NCT01169350",
      "title": "18F-Fluoromisonidazole and Fludeoxyglucose F 18 PET/CT Patients With Soft Tissue Sarcoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Adult Soft Tissue Sarcoma",
        "Stage I Adult Soft Tissue Sarcoma",
        "Stage II Adult Soft Tissue Sarcoma",
        "Stage III Adult Soft Tissue Sarcoma",
        "Stage IV Adult Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "fludeoxyglucose F 18",
          "type": "RADIATION"
        },
        {
          "name": "18F-fluoromisonidazole",
          "type": "OTHER"
        },
        {
          "name": "positron emission tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "computed tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2010-02",
      "completion_date": "2013-08",
      "has_results": true,
      "last_update_posted_date": "2017-11-17",
      "last_synced_at": "2026-11-22T21:30:04.208Z",
      "location_count": 2,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01169350"
    },
    {
      "nct_id": "NCT04216290",
      "title": "A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Urothelial Carcinoma",
        "Stage III Bladder Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biopsy of Bladder",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Cystoscopy",
          "type": "PROCEDURE"
        },
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Mitomycin",
          "type": "DRUG"
        },
        {
          "name": "Patient Observation",
          "type": "OTHER"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2021-03-17",
      "completion_date": "2027-05-19",
      "has_results": true,
      "last_update_posted_date": "2026-11-17",
      "last_synced_at": "2026-11-22T21:30:04.208Z",
      "location_count": 216,
      "location_summary": "Anchorage, Alaska • Fort Smith, Arkansas • Hot Springs, Arkansas + 153 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04216290"
    },
    {
      "nct_id": "NCT05770531",
      "title": "Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic HER2-Negative Breast Carcinoma",
        "Metastatic Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Sacituzumab Govitecan",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2023-10-03",
      "completion_date": "2028-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-24",
      "last_synced_at": "2026-11-22T21:30:04.208Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05770531"
    },
    {
      "nct_id": "NCT06532279",
      "title": "Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",
        "Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",
        "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",
        "Head and Neck Squamous Cell Carcinoma",
        "Hypopharyngeal Squamous Cell Carcinoma",
        "Laryngeal Squamous Cell Carcinoma",
        "Nasopharyngeal Squamous Cell Carcinoma",
        "Oral Cavity Squamous Cell Carcinoma",
        "Oropharyngeal Squamous Cell Carcinoma",
        "Stage 0 Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8",
        "Stage 0 Hypopharyngeal Carcinoma AJCC v8",
        "Stage 0 Nasopharyngeal Carcinoma AJCC v8",
        "Stage 0 Oropharyngeal (p16-Negative) Carcinoma AJCC v8",
        "Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8",
        "Stage I Hypopharyngeal Carcinoma AJCC v8",
        "Stage I Laryngeal Cancer AJCC v8",
        "Stage I Lip and Oral Cavity Cancer AJCC v8",
        "Stage I Nasopharyngeal Carcinoma AJCC v8",
        "Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8",
        "Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8",
        "Stage II Hypopharyngeal Carcinoma AJCC v8",
        "Stage II Laryngeal Cancer AJCC v8",
        "Stage II Lip and Oral Cavity Cancer AJCC v8",
        "Stage II Nasopharyngeal Carcinoma AJCC v8",
        "Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8",
        "Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8",
        "Stage III Hypopharyngeal Carcinoma AJCC v8",
        "Stage III Laryngeal Cancer AJCC v8",
        "Stage III Lip and Oral Cavity Cancer AJCC v8",
        "Stage III Nasopharyngeal Carcinoma AJCC v8",
        "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8",
        "Stage IVA Hypopharyngeal Carcinoma AJCC v8",
        "Stage IVA Laryngeal Cancer AJCC v8",
        "Stage IVA Lip and Oral Cavity Cancer AJCC v8",
        "Stage IVA Nasopharyngeal Carcinoma AJCC v8",
        "Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8",
        "Stage IVB Hypopharyngeal Carcinoma AJCC v8",
        "Stage IVB Laryngeal Cancer AJCC v8",
        "Stage IVB Lip and Oral Cavity Cancer AJCC v8",
        "Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8",
        "Stomatitis"
      ],
      "interventions": [
        {
          "name": "Best Practice",
          "type": "OTHER"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Image Guided Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Intensity-Modulated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "MnSOD Mimetic BMX-001",
          "type": "DRUG"
        },
        {
          "name": "Placebo Administration",
          "type": "DRUG"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "NRG Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 98,
      "start_date": "2025-06-23",
      "completion_date": "2032-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-11-22T21:30:04.208Z",
      "location_count": 153,
      "location_summary": "Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 126 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Surprise",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06532279"
    },
    {
      "nct_id": "NCT03778294",
      "title": "18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma",
        "Malignant Glioma"
      ],
      "interventions": [
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Fluorodopa F 18",
          "type": "OTHER"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Proton Beam Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2019-03-28",
      "completion_date": "2023-11-26",
      "has_results": true,
      "last_update_posted_date": "2025-07-03",
      "last_synced_at": "2026-11-22T21:30:04.208Z",
      "location_count": 2,
      "location_summary": "Scottsdale, Arizona • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03778294"
    },
    {
      "nct_id": "NCT05873712",
      "title": "Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Transformed Chronic Lymphocytic Leukemia",
        "Refractory Transformed Chronic Lymphocytic Leukemia",
        "Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma",
        "Recurrent Transformed B-Cell Non-Hodgkin Lymphoma",
        "Recurrent Transformed Non-Hodgkin Lymphoma",
        "Refractory Transformed Non-Hodgkin Lymphoma",
        "Refractory Transformed B-cell Non-Hodgkin Lymphoma",
        "Refractory Transformed"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Leukapheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Lisocabtagene Maraleucel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lymph Node Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Zanubrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Aseel Alsouqi",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2023-07-28",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-03",
      "last_synced_at": "2026-11-22T21:30:04.208Z",
      "location_count": 3,
      "location_summary": "New York, New York • Columbus, Ohio • Salt Lake City, Utah",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05873712"
    },
    {
      "nct_id": "NCT07195734",
      "title": "Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",
        "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",
        "Locally Recurrent Head and Neck Squamous Cell Carcinoma",
        "Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma",
        "Locally Recurrent Laryngeal Squamous Cell Carcinoma",
        "Locally Recurrent Oral Cavity Squamous Cell Carcinoma",
        "Locally Recurrent Oropharyngeal Squamous Cell Carcinoma",
        "Stage II Laryngeal Cancer AJCC v8",
        "Stage II Lip and Oral Cavity Cancer AJCC v8",
        "Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8",
        "Stage III Laryngeal Cancer AJCC v8",
        "Stage III Lip and Oral Cavity Cancer AJCC v8",
        "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8",
        "Stage IVA Laryngeal Cancer AJCC v8",
        "Stage IVA Lip and Oral Cavity Cancer AJCC v8",
        "Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8",
        "Stage IVB Laryngeal Cancer AJCC v8",
        "Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Salvage Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2026-04-24",
      "completion_date": "2033-02-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-26",
      "last_synced_at": "2026-11-22T21:30:04.208Z",
      "location_count": 115,
      "location_summary": "Tucson, Arizona • Irvine, California • Los Angeles, California + 85 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07195734"
    },
    {
      "nct_id": "NCT05886036",
      "title": "Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nodular Lymphocyte Predominant B-Cell Lymphoma",
        "Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma",
        "Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Fludeoxyglucose F-18",
          "type": "OTHER"
        },
        {
          "name": "Mosunetuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rituximab and Hyaluronidase Human",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2024-01-23",
      "completion_date": "2028-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-14",
      "last_synced_at": "2026-11-22T21:30:04.208Z",
      "location_count": 36,
      "location_summary": "Duarte, California • Aventura, Florida • Coral Gables, Florida + 31 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Coral Springs",
          "state": "Florida"
        },
        {
          "city": "Deerfield Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05886036"
    }
  ]
}